Concerns over Efficacy and Cost of Muscle Wasting Treatments
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Concerns over Efficacy and Cost of Muscle Wasting Treatments

Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

pharma
Starting a New Lab
Starting a New Lab
The Scientist Creative Services Team | Aug 6, 2020
Advice for new principal investigators starting their first research laboratories!
Activities Discovered for Some Inactive Drug Ingredients
Activities Discovered for Some Inactive Drug Ingredients
Ruth Williams | Jul 23, 2020
Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.
US Selects Two COVID-19 Vaccine Candidates for Huge Investments
US Selects Two COVID-19 Vaccine Candidates for Huge Investments
Amy Schleunes | Apr 1, 2020
The government is assisting Johnson & Johnson and Moderna with expediting clinical testing while at the same time prepping for large-scale manufacturing.
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Shawna Williams | Dec 6, 2019
The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.
Former FDA Commissioner Frank Young Dies
Former FDA Commissioner Frank Young Dies
Jef Akst | Dec 2, 2019
The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Emily Makowski | Nov 25, 2019
The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.
Some Data Backing Novartis Gene-Therapy Approval Manipulated: FDA
Some Data Backing Novartis Gene-Therapy Approval Manipulated: FDA
Nicoletta Lanese | Aug 7, 2019
The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.
How K2 and Other Synthetic Cannabinoids Got Their Start in the Lab
How K2 and Other Synthetic Cannabinoids Got Their Start in the Lab
Ashley Yeager | Nov 27, 2018
Originally intended for basic neuroscience research, the drugs were ultimately hijacked for illicit recreational use.
Serum Survey Reveals Protein Patterns of Ill Health
Serum Survey Reveals Protein Patterns of Ill Health
Ruth Williams | Aug 2, 2018
Analyses of blood from thousands of people show distinct protein profiles are linked to complex diseases of aging.
FDA Approves First Marijuana-Derived Drug
FDA Approves First Marijuana-Derived Drug
Shawna Williams | Jun 25, 2018
As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.
CRISPR Patent Dispute Heard in Federal Court
CRISPR Patent Dispute Heard in Federal Court
Jim Daley | May 1, 2018
In an ongoing legal battle, the University of California, Berkeley has challenged the Broad Institute’s patent claims on the gene editing technology.
NIH Won’t Use Industry Money for Opioid Research Initiative
NIH Won’t Use Industry Money for Opioid Research Initiative
Shawna Williams | Apr 19, 2018
The announcement comes after an agency working group recommends against an industry partnership on ethical grounds.
Infographic: Cancer Drug Pairings
Infographic: Cancer Drug Pairings
Anna Azvolinsky | Mar 31, 2018
Researchers use several different strategies to deliver a one-two punch.
Pfizer to Halt Alzheimer’s and Parkinson’s Drug Research
Pfizer to Halt Alzheimer’s and Parkinson’s Drug Research
Jim Daley | Jan 7, 2018
The company’s recent effort to find new treatments for Alzheimer’s ended in disappointment.
Dengue Vaccine Program Halted Over Safety Issues
Dengue Vaccine Program Halted Over Safety Issues
Shawna Williams | Dec 5, 2017
The drug may worsen future infections for people who haven't already been exposed to the virus.
Clinical Trial Reporting for Pharma-Sponsored Trials Shows Improvement
Clinical Trial Reporting for Pharma-Sponsored Trials Shows Improvement
Diana Kwon | Dec 4, 2017
The Good Pharma Scorecard finds some big pharmaceutical companies are meeting legal standards for disclosing results—but many studies still go unreported.
Study: Hidden Conflicts of Interest Permeate Medicine
Study: Hidden Conflicts of Interest Permeate Medicine
Diana Kwon | Jan 18, 2017
Three investigations reveal the influence of industry money in patient advocacy groups, treatment guidelines, and Twitter feeds. 
Novartis Buys US Drugmaker for Up To $665 Million
Novartis Buys US Drugmaker for Up To $665 Million
Tracy Vence | Nov 22, 2016
The Swiss pharma giant is acquiring Oklahoma-based Selexys Pharmaceuticals, a maker of drugs for inflammatory and thrombotic diseases.
The Growth of Iowa Biotech
The Growth of Iowa Biotech
Jenny Rood | Aug 1, 2016
The state’s industry draws inspiration from medicine as well as agriculture.